Ubiquitin fold modifier 1 (UFM1) is a 9.1kDa ubiquitin-like protein with 85 amino acids. It is encoded by the gene mapped to human chromosome 13q13.3. UFM1 is expressed both in nucleus and cytoplasm. UFM1 is expressed in human cells as a precursor with a C-terminal Ser-Cys dipeptide extension, which is then activated by ubiquitin-like modifier activating enzyme 5 (UBA5) by cleaving C- terminal end.
Synonyms: Anti-BA131P10.1; Anti-C13orf20; Anti-Ubiquitin-fold modifier 1
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Ubiquitin-fold modifier 1 (UFM1) together with activating signal co-integrator 1 (ASC1) plays a vital role in regulation of breast cancer. Alteration in the UFM1 pathway due to ubiquitin-like modifier activating enzyme 5 (UBA5) mutation, leads to autosomal recessive cerebellar ataxia (ARCA).
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC